The Next Agonist
PT-141 and Melanotan II are not the same drug
The search that pairs these two names is usually looking for a substitute. There isn’t one. PT-141 is the old code for an approved prescription drug. Melanotan II is an unapproved peptide. They came out of the same research line. They are not interchangeable, and this page will not tell you how to obtain either.
What PT-141 actually is
PT-141 was the research name. The drug is bremelanotide, sold as Vyleesi. The FDA approved it on 21 June 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women — low sexual desire that causes marked distress, in that population, on a prescription. (Vyleesi prescribing information, 2019; Dhillon and Keam, Drugs, 2019.) It is a melanocortin-receptor agonist aimed at the central circuits of sexual response, not at a tan. The label is one sentence long in the way that matters: one population, one disorder, a manufacturer, a regulator. This page does not reprint a dose. A dose is not what the query is asking, and it is not what distinguishes the two.
The origin is already told. A self-experiment with Melanotan II produced an arousal effect the tanning program had not been built to find, and Palatin developed that effect into bremelanotide rather than into a tan. (The accident.) That is history. It is not a reason to treat the parent peptide as the child drug.
What a listing called PT-141 usually is
The approved drug has a brand, a label, and a pharmacy. The code PT-141 also circulates on the research-chemical market, next to Melanotan II, BPC-157, and the rest of the peptide menu. LegitScript’s 2025 dataset, cited in how it’s sold now, named that menu as one trade. A page that says “not for human consumption” and then sells a vial under a retired research code is not dispensing Vyleesi. It is wearing the costume.
The costume does not make the contents safe, identical, or legal to sell for the use the searcher has in mind. Australia’s assays of Melanotan products already showed that a label on this market is not a specification. (What’s in the vial.) There is no reason to assume a bottle marked PT-141 is held to a standard the Melanotan bottles were not.
What Melanotan II is not
Melanotan II has never been approved for sexual desire, for tanning, or for anything else. It is not a cheaper Vyleesi. It is not “the same peptide, basically.” Using an unapproved compound because it shares an ancestor with an approved one is how the gray market launders a substitution. This site does not publish sourcing, suppliers, or usage guidance for that substitution — not as comparison, not as harm reduction, not as history.
The approved drug is the one with the label. The unapproved peptide is the cautionary tale. If a future melanocortin medicine earns a wider label, it will earn it in a trial, not in a checkout.
Common questions
Is PT-141 the same as Melanotan II?
No. PT-141 is the old research name for bremelanotide, approved by the FDA in June 2019 as Vyleesi for one indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women. Melanotan II has never been approved for any use. A shared origin is not a shared product.
Is PT-141 FDA approved?
The prescription drug is. Vyleesi (bremelanotide) is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women. A peptide sold online under the old code PT-141, with a research-only disclaimer, is not that prescription. It is the same costume the gray market uses for Melanotan II.
Can Melanotan II replace Vyleesi?
No. Melanotan II is an unapproved peptide. It is not a substitute for a prescription drug, and this site does not publish sourcing, dosing, or usage guidance for it. The approved drug has a label, a manufacturer, and a narrow indication. The vial has none of those.